PHASE I EVALUATION OF PHENYLBUTYRATE IN REFRACTORY MALIGNANT GLIOMA

$16,409M01FY2000RRNIH

University Of Texas Hlth Sci Ctr San Ant, San Antonio TX

Investigators

Linked publications & trials

Paper 38816203 Paper 38746210 Paper 38741246 Paper 38204926 Paper 38051041 Paper 37978826 Paper 37226675 Paper 36933679 Paper 36280384 Paper 35926332 Paper 35562076 Paper 35453142 Paper 35019976 Paper 34753805 Paper 34412057 Paper 34219361 Paper 34166655 Paper 33707304 Paper 33627633 Paper 33597215 Paper 33178459 Paper 33168654 Paper 33057385 Paper 32845968 Paper 32841523 Paper 32564066 Paper 32388179 Paper 32281153 Paper 32134326 Paper 32128240 Paper 32085906 Paper 31898874 Paper 31559418 Paper 31338998 Paper 31131339 Paper 31112370 Paper 30997482 Paper 30900413 Paper 30487263 Paper 30421851 Paper 30201101 Paper 30065651 Paper 29846553 Paper 29545462 Paper 29159267 Paper 29086498 Paper 29053861 Paper 28958022 Paper 28940967 Paper 28678345 Paper 28470881 Paper 28031420 Paper 27685338 Paper 27676466 Paper 27595918 Paper 27471785 Paper 27465756 Paper 27271190 Paper 27208378 Paper 27142425 Paper 27129676 Paper 27114389 Paper 27028282 Paper 26833676 Paper 26578543 Paper 26489030 Paper 26487792 Paper 26386801 Paper 26305897 Paper 26094705 Paper 26049399 Paper 25887158 Paper 25780952 Paper 25707379 Paper 25666468 Paper 25592187 Paper 25573655 Paper 25546032 Paper 25452229 Paper 25405847 Paper 25127483 Paper 25102180 Paper 25048381 Paper 24986062 Paper 24855155 Paper 24853636 Paper 24771618 Paper 24763850 Paper 24619151 Paper 24533998 Paper 24532116 Paper 24445103 Paper 24307184 Paper 24273587 Paper 24271651 Paper 24174392 Paper 24141640 Paper 24081232 Paper 24060607 Paper 24029427

Abstract

Phenylbutyrate is a potential tumor differentiating agent and cytoxic agent which could alter tumor growth and progression, slow or inhibit metastases, and/or effect response to other forms of therapy. It does not have the systemic toxicities of other differentiating agents. This study will determine the maximum tolerated dose of phenylbutyrate given orally three times a day to patients with refractory CNS tumors before evidence of tumor progression. The study will also determine the therapeutic activity of the study drug.

View original record on NIH RePORTER →